drugset / Trial / NCT01365104
Modulation of Cerebral Blood Flow Using Iron Chelators
Phase 0
Completed
97 enrolled
Brigham and Women's Hospital
National Institute on Aging (NIA) · collab
RandomizedCrossoverTriple-blindPrevention
Summary
The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.
Timeline
- Start
- 2008-03
- Primary completion
- 2012-06
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferoxamine | Other / unclassified | 60 mg/kg | Intravenous |